Author

Linta Kuncheria

Observed name: Kuncheria, Linta

Institution: Replimune Group, Inc. (United States)

Observed institution: Replimune Group, Inc. (United States)

OpenAlex ID: A5059280404

Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1

2019 · Suzanne Thomas, Linta Kuncheria, et al. · Journal for ImmunoTherapy of Cancer · 168

Effects of oncolytic immunotherapy with RP1 (vusolimogene oderparepvec) on immune cells mediate responsiveness to anti-PD-1 via STING-mediated interferon signaling

2026 · Victoria Roulstone, Joan Kyula, et al. · Journal for ImmunoTherapy of Cancer · 5

Abstract 1917: Immunomodulatory effects of a novel, enhanced potency gibbon ape leukaemia virus (GALV) fusogenic membrane glycoprotein-expressing herpes simplex virus platform with increased efficacy combined with anti PD-1 therapy

2021 · Victoria Roulstone, Joan Kyula, et al. · Cancer Research · 3

Abstract 6639: Preclinical characterization and clinical biomarker studies with RP3, a novel oncolytic immunotherapy expressing a fusogenic protein, a human anti-CTLA-4 antibody, hCD40L and h4-1BBL

2023 · Praveen K. Bommareddy, Kevin Harrington, et al. · Cancer Research

Works count: 6

Citation count: 176

H-index: 3

I10-index: 1